GRP78 targeting : Hitting two birds with a stone

Copyright © 2020 Elsevier Inc. All rights reserved..

BACKGROUND: Glucose regulating protein 78 (GRP78) is one member of the Heat Shock Protein family of chaperone proteins (HSPA5) found in eukaryotes. It acts as the master of the Unfolded Protein Response (UPR) process in the lumen of the Endoplasmic Reticulum (ER).

SCOPE: Under the stress of unfolded proteins, GRP78 binds to the unfolded proteins to prevent misfolding, while under the load of the unfolded protein, it drives the cell to autophagy or apoptosis. Several attempts reported the overexpression of GRP78 on the cell membrane of cancer cells and cells infected with viruses or fungi.

MAJOR CONCLUSIONS: Cell-surface GRP78 is used as a cancer cell target in previous studies. Additionally, GRP78 is used as a drug target to stop the progression of cancer cells by different compounds, including peptides, antibodies, and some natural compounds. Additionally, it can be used as a protein target to reduce the infectivity of different viruses, including the pandemic SARS-CoV-2. Besides, GRP78 targeting is used in diagnosis and imaging modalities using radionuclides.

GENERAL SIGNIFICANCE: This review summarizes the various attempts that used GRP78 both in therapy (fighting cancer, viral and fungal infections) and diagnosis (imaging).

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:260

Enthalten in:

Life sciences - 260(2020) vom: 01. Nov., Seite 118317

Sprache:

Englisch

Beteiligte Personen:

Elfiky, Abdo A [VerfasserIn]
Baghdady, Ahmed M [VerfasserIn]
Ali, Shehab A [VerfasserIn]
Ahmed, Marwan I [VerfasserIn]

Links:

Volltext

Themen:

Antineoplastic Agents
BiP
Biological Products
Cancer-targeting
Endoplasmic Reticulum Chaperone BiP
GRP78
HSPA5 protein, human
Heat-Shock Proteins
Journal Article
Natural compounds
Peptide inhibitors
Review
SARS-CoV-2

Anmerkungen:

Date Completed 09.11.2020

Date Revised 02.03.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.lfs.2020.118317

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM314150374